• Home
  • NEW DAY MEDICINE
  • 6 (38) 2021
  • 37 -6 (38) 2021 — Mukhammedjanova M.Kh., Ergashev B.B., — ARITHMOGENIC EFFECTS OF ANTITUMOR THERAPY FOR ONCOLOGICAL DISEASES

37 -6 (38) 2021 — Mukhammedjanova M.Kh., Ergashev B.B., — ARITHMOGENIC EFFECTS OF ANTITUMOR THERAPY FOR ONCOLOGICAL DISEASES

ARITHMOGENIC EFFECTS OF ANTITUMOR THERAPY FOR ONCOLOGICAL DISEASES

Mukhammedjanova M.Kh., Bukhara State Medical Institute

Ergashev B.B., Bukhara State Medical Institute

Ubaydova D.S., Bukhara State Medical Institute

Jumaeva M.F. Bukhara State Medical Institute

Resume

Many anticancer drugs have potential arrhythmogenic effects. At the same time, the question of predictors of the realization of the proarrhythmic action of targeted chemotherapy has been insufficiently studied.

The purpose of this review article is to analyze modern literary sources on the frequency of development and features of the course of arrhythmias arising against the background of anticancer therapy of oncological diseases.

Key words: oncopathology, arrhythmias, chemotherapy, complication, targeted therapy

First page

216

Last page

220

For citation: Mukhammedjanova M.Kh., Ergashev B.B., Ubaydova D.S., Jumaeva M.F. ARITHMOGENIC EFFECTS OF ANTITUMOR THERAPY FOR ONCOLOGICAL DISEASES //New Day in Medicine 6(38)2021 216-220 https://cutt.ly/TY59atJ

LIST OF REFERENCES:

  1. Гумерова К.С., Сахаутдинова Г.М., Полякова И.М. Кардиоваскулярная токсичность, индуцированная применением противоопухолевых препаратов, и современные методы лечения опухолевых новообразований. Креативная хирургия и онкология. 2019;9(4):285-292.
  2. Курмукови И.А. др. Нарушение ритма сердца после химиотерапии// Клиническая онкогематология. 2011 №4 с.38-44
  3. Потиевская В.И., Ахобеков А.А., Кононова Е.В. Взаимосвязь нарушений ритма сердца с противоопухолевой те- рапией онкологических заболеваний. Кардиоваскулярная терапия и профилактика. 2020;19(5):2417
  4. Челомбитько Е.Г., Королев С.В., Конев А.В., Плохова Е.В., Дундуа Д.П. Тахиаритмии у пациентов с онкологическими заболеваниями//Клиническая практика . 2017. №4 стр.76-88
  5. 2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines / The Task Force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC) // Eur. Heart. J. – 2016. – Vol. 21, № 37 (36). – Р. 2768–2801.
  6. Abdel-Wahab N, Shah M, Suarez-Almazor M E. Adverse events associated with immune checkpoint blockade in patients with cancer: A systematic review of case reports. PLOS ONE. 2016;11(7):e0160221.
  7. Armenian Saro H et.all. Prevention and Monitoring of Cardiac Dysfunction in Survivors of Adult Cancers: American Society of Clinical Oncology Clinical Practice Guideline. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2017;35:893–911.
  8. Cardinale Daniela, Biasillo Gina, Salvatici Michela, Sandri Maria Teresa, Cipolla Carlo Maria. Using biomarkers to predict and to prevent cardiotoxicity of cancer therapy. Expert review of molecular diagnostics. 2017;17:245–256.
  9. Chang Hui-Ming, Moudgil Rohit, Scarabelli Tiziano, Okwuosa Tochukwu M, Yeh Edward T H. Cardiovascular Complications of Cancer Therapy: Best Practices in Diagnosis, Prevention, and Management: Part 1. Journal of the American College of Cardiology. 2017;70:2536–2551.
  10. Chen C L. Cardiovascular prevention in the cancer survivor. Current Atherosclerosis Reports. 2015;17(6):1–10.
  11. Cheungpasitporn W., Kopecky S.L., Specks U., Bharucha K., Fervenza F.C. Non-ischemic cardiomyopathy after rituximab treatment for membranous nephropathy. J Renal Inj Prev. 2017;6(1):18-25.
  12. Higgins Angela Y, O’Halloran Thomas D, Chang James D. Chemotherapy-induced cardiomyopathy. Heart failure reviews. 2015;20:721–730.
  13. U.S. National Library of Medicine: National Institutes of Health; 2018. Available from: https://www.nih.gov

file

download